Literature DB >> 21844496

Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus.

Sarina A Piha-Paul1, Philip R Cohen, Razelle Kurzrock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21844496     DOI： 10.1200/JCO.2011.36.2095

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  16 in total

1.  Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway.

Authors:  Floyd Christopher Holsinger; Sarina Anne Piha-Paul; Filip Janku; David S Hong; Johnique T Atkins; Apostolia M Tsimberidou; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2013-01-28       Impact factor: 44.544

2.  The "shield sign" in two men with metastatic salivary duct carcinoma to the skin: cutaneous metastases presenting as carcinoma hemorrhagiectoides.

Authors:  Philip R Cohen; Victor G Prieto; Sarina A Piha-Paul; Razelle Kurzrock
Journal:  J Clin Aesthet Dermatol       Date:  2012-09

3.  Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.

Authors:  Gerald S Falchook; Scott M Lippman; Christel C Bastida; Razelle Kurzrock
Journal:  Head Neck       Date:  2013-10-19       Impact factor: 3.147

4.  Trastuzumab for the treatment of salivary duct carcinoma.

Authors:  Sewanti A Limaye; Marshall R Posner; Jeffrey F Krane; Maria Fonfria; Jochen H Lorch; Deborah A Dillon; Aditya V Shreenivas; Roy B Tishler; Robert I Haddad
Journal:  Oncologist       Date:  2013-02-21

5.  Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.

Authors:  Pierre Saintigny; Yoshitsugu Mitani; Kristen B Pytynia; Renata Ferrarotto; Dianna B Roberts; Randal S Weber; Merrill S Kies; Sankar N Maity; Sue-Hwa Lin; Adel K El-Naggar
Journal:  Cancer       Date:  2018-10-05       Impact factor: 6.860

Review 6.  Salivary gland carcinomas.

Authors:  Tobias Ettl; Stephan Schwarz-Furlan; Martin Gosau; Torsten E Reichert
Journal:  Oral Maxillofac Surg       Date:  2012-07-29

7.  Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer.

Authors:  Tobias Ach; Katharina Zeitler; Stephan Schwarz-Furlan; Katharina Baader; Abbas Agaimy; Christian Rohrmeier; Johannes Zenk; Martin Gosau; Torsten E Reichert; Gero Brockhoff; Tobias Ettl
Journal:  Virchows Arch       Date:  2012-12-15       Impact factor: 4.064

8.  Carcinoma ex-pleomorphic adenoma of the salivary glands has a high risk of progression when the tumor invades more than 2.5 mm beyond the capsule of the residual pleomorphic adenoma.

Authors:  Miguel Rito; Isabel Fonseca
Journal:  Virchows Arch       Date:  2015-12-05       Impact factor: 4.064

9.  Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.

Authors:  Simion I Chiosea; Lester D R Thompson; Ilan Weinreb; Julie E Bauman; Alyssa M Mahaffey; Caitlyn Miller; Robert L Ferris; William E Gooding
Journal:  Cancer       Date:  2016-07-05       Impact factor: 6.860

10.  High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy.

Authors:  Han Liu; Li Du; Ru Wang; Chao Wei; Bo Liu; Lei Zhu; Pixu Liu; Qiang Liu; Jiang Li; Shi-Long Lu; Jing Xiao
Journal:  Oncotarget       Date:  2015-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.